{"entity":{"id":"nct07900165","kind":"trial","name":"Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of Varsetatug masetecan run by CytomX Therapeutics, not yet recruiting.","summary":"Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer is a phase 1/2 interventional study registered as NCT07900165 by CytomX Therapeutics, with 368 participants planned, started 2026-12. Conditions recorded: Colo-rectal Cancer. Interventions recorded: varsetatug masetecan, bevacizumab + 5-FU + leucovorin and bevacizumab.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07900165","url":"https://clinicaltrials.gov/study/NCT07900165"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["varsetatug-masetecan"],"companies":["cytomx-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07900165","phase":"1/2","setting":"A Trial of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Participants With Metastatic Colorectal Cancer","sponsor":"CytomX Therapeutics","enrolled":368,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07900165/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"varsetatug-masetecan","kind":"drug","name":"Varsetatug masetecan","route":"/drugs/varsetatug-masetecan/"}],"company":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"}]}}